Weight Loss

Is liposomal berberine the new weight-loss fix or just online hype?

Promoted as a natural shortcut to fat loss, liposomal berberine is drawing caution from doctors over safety, drug interactions and misleading comparisons with Ozempic

Popular weight-loss drugs shouldn't carry suicide warnings, FDA says

Federal regulators have told drugmakers Novo Nordisk and Eli Lilly to remove label warnings about potential suicidal thoughts and behaviours from their blockbuster weight-loss medications. The US Food and Drug Administration on Tuesday said a comprehensive review found no increased risk related to suicide among users of the GLP-1 drugs for obesity, including Novo Nordisk's Wegovy and Saxenda and Eli Lilly's Zepbound. A preliminary review in January 2024 showed no link between the drugs and suicidal thought or actions, the FDA said. At that time, however, officials said they could not rule out that a small risk may exist. The new analysis puts those concerns to rest. Labeling for other drugs known as GLP-1 receptor agonists approved to treat diabetes carried no such warnings, the agency noted. Today's FDA action will ensure consistent messaging across the labelling for all FDA-approved GLP-1 RA medications, officials said.

Why weight returns fast after stopping obesity drugs? Homeostasis explained

Here's how homeostasis, hormones and obesity drugs affect why lost weight often returns faster than expected

Stopping Ozempic or Mounjaro? The weight may come back faster than you think

New research shows people regain weight far faster after stopping obesity drugs than after dieting, with benefits fading quickly and raising questions about how long GLP-1 medicines need to be taken

How eggs can help you come off Wegovy, solve problem of weight regain

Eating eggs has been repeatedly shown to help people feel fuller for longer and eat less at later meals, including among people who are overweight or obese

GLP-1 launches inject over 2x rise in weight-loss market sales in 2025

Experts say OAds, insulin to dominate anti-diabetes market, with semaglutide patent loss leading to possible price erosion, value moderation

The viral 'oatzempic' drink trend: Does this oat blend actually work?

Social media is hailing Oatzempic as a natural way for weight-loss. But does it actually work, and is it safe to rely on?

Five ways to improve your health in 2026 without focusing on weight loss

Many New Year resolutions focus on weight but long-term health is shaped by wider habits and small realistic steps can add up to meaningful health gains over the year

Novo Nordisk secures US FDA approval for first weight-loss pill

US-listed shares of Novo jumped 8 per cent and Lilly fell 1 per cent in extended trading after the approval announcement

Novo gets US nod for Wegovy pill, eyes January launch in obesity market

Novo will start selling the pill, the first of the blockbuster GLP-1 class, in the US in early January, the company said in a statement Monday

How fatherhood helped Ed Sheeran lose 14 kg and transform his health

Fatherhood, not fame, became the turning point in Ed Sheeran's health journey, prompting gradual lifestyle changes that improved both his physical and mental wellbeing

Mounjaro and the brain: Why cravings fade at first, then return later

A rare brain-recording study found tirzepatide briefly muted activity linked to 'food noise'; months later the signals and intrusive thoughts returned, hinting at limits to its effect

How isabgol improves gut function and supports weight management

Long used for digestion, psyllium husk or isabgol is now being linked to better gut health, appetite control and modest weight loss. Here's how it works and how to use it safely

Ozempic in India: What it does and how it fits into a growing health crisis

From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions

Novo Nordisk launches Ozempic in India at ₹2,200/week amid patent battles

Ozempic debuts in India at ₹2,200 per week, offering a new treatment option for type 2 diabetes as demand grows for effective and easy-to-use metabolic health therapies

Delhi HC allows Sun Pharma to manufacture, export its weight loss drug

The approval marks a major win for Sun Pharma in its patent dispute with Danish drugmaker Novo Nordisk, the company that manufactures weight loss drug Ozempic

Healthify seeks more weight-loss drug partnerships after Novo Nordisk deal

The deal marks Healthify's first such partnership with a drugmaker, and it hopes similar agreements will boost its paid subscriber base

Can Ozempic trigger depression or suicidal thoughts? Australia weighs in

Australia has issued a safety alert on GLP-1 drugs after reviewing reports of depression and suicidal thoughts; while there is no proven causal link, regulators want users to stay alert

WHO calls for 'responsible use' of GLP-1 drugs for long term obesity care

The guideline reframes obesity as a chronic disease needing lifelong care, recommending GLP-1 therapies with behavioural support rather than relying on medication alone

Good old kalonji may help control fat and cholesterol, says new study

A new clinical trial shows that kalonji, long used in Indian kitchens, may help lower cholesterol and slow fat formation, offering a natural metabolic boost alongside regular diet and lifestyle habits